Gates Foundation Strategic Investment Fund Logo

Press Release: Arsanis Announces Closing of Initial Public Offering

November 20, 2017 WALTHAM, Mass. and VIENNA–(BUSINESS WIRE  Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the closing of its initial public offering of 4,600,000 shares of its Read More